March 2009

Cytokine gene polymorphisms across tuberculosis clinical spectrum in Pakistani patients.

Ambreen Ansari  
*Aga Khan University*

Najeeha Talat  
*Aga Khan University*

Bushra Jamil  
*Aga Khan University*, bushra.jamil@aku.edu

Zahra Hasan  
*Aga Khan University*, zahra.hasan@aku.edu

Tashmeem Razzaki  
*Sindh Institute of Urology and Transplantation*

See next page for additional authors

Follow this and additional works at: [https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol](https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol)

Part of the [Microbiology Commons](https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol), and the [Pathology Commons](https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol)

Recommended Citation

Ansari, A., Talat, N., Jamil, B., Hasan, Z., Razzaki, T., Dawood, G., Hussain, R. (2009). Cytokine gene polymorphisms across tuberculosis clinical spectrum in Pakistani patients. *Plos One*, 4(3), e4778.

Available at: [https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/86](https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/86)
Cytokine Gene Polymorphisms across Tuberculosis Clinical Spectrum in Pakistani Patients

Ambreen Ansari1, Najeeha Talat1, Bushra Jamil2, Zahra Hasan1, Tashmeem Razzaki3, Ghaffar Dawood4, Rabia Hussain1*

1 Pathology & Microbiology Department, The Aga Khan University, Karachi, Pakistan, 2 Pathology, Microbiology & Medicine Department, The Aga Khan University, Karachi, Pakistan, 3 Sindh Institute of Urology and Transplantation, Karachi, Pakistan, 4 Masoomeen General Hospital, Karachi, Pakistan

Abstract

Background: Pakistan ranks 7th globally in terms of tuberculosis (TB) disease burden (incidence 181/100000 pop./yr; prevalence of 329/pop./yr). Reports from different populations show variable associations of TB susceptibility and severity with cytokine gene polymorphisms. Tuberculosis clinical severity is multi-factorial and cytokines play a pivotal role in the modulation of disease severity. We have recently reported that the ratio of two key cytokines (IFNγ and IL10) show significant correlation with the severity spectrum of tuberculosis. The objective of this current study was to analyze the frequency of cytokine gene polymorphisms linked to high and low responder phenotypes (IFNγ +874 T+→A0 and IL10 −1082 G0→A0) in tuberculosis patients.

Methods and Findings: Study groups were stratified according to disease site as well as disease severity: Pulmonary N = 111 (Minimal, PMN = 19; Moderate, PMD = 63; Advance, PAD = 29); Extra-pulmonary N = 67 (Disseminated DTB = 20, Localized LTB = 47) and compared with healthy controls (TBNA = 188). Genotype analyses were carried out using amplification refractory mutation system-PCR (ARMS-PCR) and stimulated whole blood (WB) culture assay was used for assessing cytokine profiles. Our results suggest that the IFNγ +874 TT genotype and T allele was overrepresented in PMN (p = 0.01) and PMD (p = 0.02). IFNγ +874 TT in combination with IL10 GG genotype showed the highest association (χ2 = 6.66, OR = 6.06, 95% CI = 1.31–28.07, p = 0.01). IFNγ A+0 on the other hand in combination with IL10 GG increased the risk of PAD (OR = 5.26; p = 0.005) and DTB (OR = 3.59; p = 0.045).

Conclusion: These findings are consistent with the role of IL10 in reducing collateral tissue damage and the protective role of IFNγ in limiting disease in the lung.

Introduction

Pakistan ranks 7th globally in terms of tuberculosis disease burden with an incidence of 181/100000 pop./yr and a prevalence of 329/pop./yr. Several reports from different countries have shown that household contacts of active pulmonary tuberculosis are at much higher risk of latent infection that range from 30–80% depending on the intensity of tuberculosis disease transmission [1–4]. Only ten percent of those latently infected individuals develop TB disease during their lifetime [5]. Identification of these high-risk individuals in recently exposed/infected individuals is of great importance to TB Control Programs for reducing the disease burden in the community. Association of pathological severity with increased circulating levels of different pro-inflammatory and or down-regulatory cytokines in tuberculosis is fairly well established [6]. An increasing number of studies have shown that single nucleotide polymorphisms (SNPs) located in the promoter or coding regions of cytokine genes result in differential cytokine secretion due to altered transcriptional activation. In humans, families with SNPs in IFNγ receptor 1 [7,8] genes have shown Mendelian susceptibility to tuberculosis. Single nucleotide polymorphisms (SNPs) located in the first intron of the IFNγ gene (at position +874) have shown variable associations with tuberculosis disease susceptibility and severity [9]. IFNγ (+874T→A) polymorphism is located within a putative NF-kb binding site and shows preferential binding to the T allele and correlates with high IFNγ producer phenotype [10]. Similarly polymorphisms in IL10 [11] linked to high and low producer phenotypes have shown conflicting associations with tuberculosis disease susceptibility and disease severity in different patient populations [12,13]. This is not surprising as, although IFNγ may be a key cytokine in activation of macrophages for mycobacterial stasis and killing [14], disease severity outcomes in tuberculosis depend on the balance among several different cytokines in situ, depending on the disease site. IL10 is particularly important in reducing collateral tissue damage, particularly in the lung by dampening macrophage activation and by indirectly antagonizing IFNγ function [15]. We have recently reported that
the ratio of these two key cytokines (IFNγ/IL10) shows significant
correlation with clinical severity in extra-pulmonary tuberculosis
[16], with higher IFNγ/IL10 ratio relating to less severe disease.
We have now extended these studies to analyze the frequency of
high and low responder cytokine phenotypes (IFNγ +874 T→A
and IL10 −1082 G→A) to analyze the relationship of these
SNPs with clinical severity of tuberculosis. Our results show that
SNPs in IFNγ are significantly related to site of TB disease
(Pulmonary vs. Extrapulmonary) while combinations of SNPs in
IFNγ and IL10 genes are important determinants of TB disease
severity. Our results therefore substantiate our aim of the study.

Results

Demographic characteristics of the study groups

There were no significant differences in age in TBNA and TBA
groups (Table 1). The ratio of females was significantly higher
(p<0.05) in TBA compared to TBNA. However, no significant
association of genotype with age or sex was observed in both TBA
and TBNA (p>0.05) using multiple logistic regression analysis (data
not shown).

Relationship of genotype and phenotype of IFNγ
(+874T→A) and IL10 (−1082 G→A) in TBNA

Figure 1 shows the relationship of cytokine secretion in response
to mycobacterial antigen stimulation with different genotypes
IFNγ (+874 T→A) and IL10 (−1082 G→A). We found IFNγ
T7 and IL10 LL to be the high producer phenotype in response to
mycobacterial antigens. We next looked at the frequency of these
genotypes in association with disease severity.

Distinct IFNγ +874 but not IL10 −1082 genotype SNPs
are associated with different disease sites and not with
TB susceptibility

Cytokine genotypes and alleles frequencies in all patient groups
were compared with healthy controls (Tables 3 & 4). IFNγ
+874T→A genotype distribution was in Hardy-Weinberg equilib-
rium for both patients and controls (TBA; p = 0.607 and TBNA;
p = 1.0). On the other hand, IL10 −1082G→A polymorphism
showed deviation from HWE due to excess of heterozygosity (TBA
and TBNA; p = 0.00004). Cases and controls were compared using
χ², odds ratios (OR) and their confidence intervals, (95% CI). A p
value of <0.05 was considered significant. Different cytokine
genotypes and alleles showed distinct associations with different
disease types as described below.

IFNγ +874 TT genotype showed significant association with
PTB (χ² = 6.05, p = 0.034) (Table 3). This association was
restricted to the T allele (Table 4). In terms of disease severity in
the lung this association was restricted to PMN and PMD and was
not seen with PAD. Similarly, no association was observed with
ETB or stratified ETB on the basis of disease severity (DTB vs.
LTB). When we compared healthy controls with latent infection
(TST+) similar and much more marked effect of IFNγ +874 TT
genotype was observed (Table 3). Therefore, genotype associations
were not only different according to disease site (PTB vs. ETB) but
there was a distinct difference between severity within a disease site
(PMD vs. PAD). These results therefore suggest that it is
inappropriate to pool tuberculosis patient with differing sites and
even severity within individual sites.

Table 1. Demographic characteristics of TB Patients and
Controls.

| Group Studied     | N   | Gender | Age (years) |
|-------------------|-----|--------|-------------|
|                   | Female (%) | Male (%) | Mean | Range |
| TB not affected controls (TBNA) | 188 | 88 (46.8) | 100 (53.1) | 28.10 | 6–70 |
| TB affected patients (TBA) | 188 | 118 (62.7) | 70 (37.2) | 33.40 | 7–81 |
| Pulmonary TB (PTB) | 111 | 65 (58.5) | 46 (41.4) | 32.0 | 10–81 |
| Pulmonary minimal (PMN) | 19 | 9 (47.3) | 10 (52.6) | 36.3 | 15–81 |
| Pulmonary moderate (PMD) | 63 | 37 (58.7) | 26 (41.2) | 33.0 | 13–70 |
| Pulmonary advance (PAD) | 29 | 19 (65.5) | 10 (34.4) | 26.2 | 10–69 |
| Extra pulmonary TB (ETB) | 67 | 47 (70.1) | 20 (29.9) | 34.5 | 7–80 |
| Disseminated TB (DTB) | 20 | 12 (60.0) | 8 (40.0) | 37.3 | 16–80 |
| Localized TB (LTB) | 47 | 35 (74.5) | 12 (25.5) | 33.3 | 7–75 |

Note: Patient stratification is as given in Materials and Methods. Abbreviations for groups are given in brackets. TBA included 10 previously treated patients.
doi:10.1371/journal.pone.0004778.t001
Multiloci genotype association with risk of disease severity across the tuberculosis disease spectrum

We have previously shown that IFNγ/IL10 ratio is a critical determinant of disease severity [16]. Since both cytokines (IFNγ, IL10) showed distinct associations with different sites and severity of TB, we also assessed if genotype combinations for these two cytokines may contribute to increased risk of TB with respect to site or severity. There were nine possible combinations. Only significant results are shown in Table 5. As expected from previous analyses (Table 3) there was a clear association of IFNγ T7h with pulmonary disease while IFNγ A4h was clearly associated with increased risk of PAD and DTB. The effect of IL10 genotype combination was much more evident with disease site rather than disease severity. IL10 GGh in combination with IFNγ A4h was associated with the highest risk for DTB (OR = 3.59; p = 0.045). The results were similar when cases were compared with TST+ controls.

Discussion

Although the effect of cytokine gene polymorphisms (SNPs) on tuberculosis disease sites or disease severity have been reported in different populations, our results for the first time show differential association of cytokine genotype combinations with either pulmonary or extra-pulmonary disease. We also report that in the lung compartment the high responder IL10 −1082 A4hi may play a critical role in limiting tissue damage in PTB. Because of careful characterization of disease in each of the group, we are able to show significant differences between groups and among groups. In addition, differences seen in both cytokines SNPs can be reconciled with their biological function. We feel that this is a very important issue despite small numbers in the stratified groups. When pulmonary patients are not stratified the sample size is sufficient for power of statistics. We have therefore given results for both pooled and stratified groups. There are very few studies, which relate genotype to phenotype. This is the strength of the current study.

There are considerable variations in allelic frequencies of cytokine gene polymorphisms in different populations [18] and therefore it is not surprising that genetic polymorphisms associated with tuberculosis have yielded conflicting results in different ethnic groups [19]. IFNγ polymorphism (+874 T7h→A4h) is the most studied polymorphism in terms of association with tuberculosis disease sites and severity. However, the reports are conflicting in that A allele is more common in patients with TB and T alleles, more common in controls in Italian [20], South African [21] Hong Kong Chinese [22]and Spanish populations [23]. In Turkey, one study reported no association [24], while a later study in the same population showed an association with the A allele [25]. In Croatia [26] an association with A allele was found only in microscopy and culture positive vs. negative TB patients. On the other hand, no association has been reported in Caucasians in Houston, Texas [27] and South Indian populations [28]. There is only one study in Colombia [29] where an association of IFNγ +874 T allele with the more localized pleural disease has been observed. Our results are in agreement with the latter study. We show that the effect of IFNγ T allele in TB affected patients is restricted to pulmonary patients with minimal/ moderate disease increasing the risk by 2–3 folds (Table 4). Both our study and the Colombian study show a much more marked association with the more protective form of tuberculosis. Some of the differences could be due to the influence of other genes linked to tuberculosis disease susceptibility [10,28,30–32]. As shown in our study, the presence of high responder IL10 −1082 A4hi may limit lung tissue damage when associated with IFNγ T7hi. Turner has reported A4 to be a low producer phenotype in response to mitogenic (ConA) stimulus [33]. Mycobacterial antigens are potent stimulators of macrophages [34] while Con A is primarily a T cell stimulator [35]. Therefore, it is possible that different stimuli may result in differential transcription of the same gene. For the current study we considered mycobacterial antigens to be the more appropriate stimulus.

A similar discrepancy is observed with IL10 (−1082 G874→A4h) where no associations were reported in Gambian [35], Korean [36] and Spanish [23] populations. An association of A allele was observed in Italian (Sicilian) [37] population, and G4 heterozygosity was associated with pulmonary TB in Cambodia [38]. Our results indicate that the homozygous GGh increases the risk of DTB when it is associated with IFNγ +874 A4h phenotype (OR = 3.59; p = 0.045). This is consistent with the low levels of mycobacterial stimulated IFNγ and IL10 from DTB [39]. We have observed an overrepresentation of G4 heterozygous genotype in our study groups and may increase the risk of PMN when associated with IFNγ A4h (Table 5). The frequency of G4 heterozygosity is highly variable in different populations ranging from 92.5% in Iranian population to 5% in Singapore Chinese [18]. Our results (70.2%) are closer to the Iranian population frequency. We further confirmed PCR amplified product by sequencing which also gave the expected SNP sequences for both IFNγ and IL10 genotypes. Therefore, it is difficult to attribute the inflation in G4 heterozygosity to artifacts in genotyping methodology as most studies have reported widely differing frequencies using ARMS PCR [18]. It is not unexpected to find linkage disequilibrium in consangious population such as the setting in which this study was conducted [17]. Further population-based studies are needed to address this issue.

Nevertheless, a consensus seems to be emerging in that the combined effect of several cytokine SNPs may play a more crucial role in disease severity [29]. These results also substantiate our earlier report [16] that IFNγ/IL10 ratio may be the critical determinant of clinical severity in both pulmonary and extra-pulmonary tuberculosis. A meta analyses recently published reinforces the critical importance of IFNγ +874 T/A as a genetic marker for TB resistance [9], while IL10 indeed had some specific effect on TB determining the disease form and severity and not with susceptibility per se. Our results are consistent with these findings.

If the rationale for analyzing cytokine gene polymorphism is to understand the pathogenesis of human disease, to identify potential markers of susceptibility or disease severity, responder vs. non-responders in therapeutic and vaccine trials, and to design novel strategies for intervention in high-risk groups, then the diversity of genetic associations warrants that such analyses are carried out in indigenous population. Our results further highlight the importance of stratification of patients in relation to disease severity, which otherwise mask the significance of associations in combined groups.

Materials and Methods

Subject studied

Gene polymorphisms were analyzed in 376 donors (TB not affected, TBNA = 188 and TB affected, TBA = 188). Table 1 shows the breakdown of TB patients in terms of clinical severity: WHO guidelines for disease classification for non HIV related tuberculosis was adopted [16,40] as follows. DTB (N = 20) had involvement of two or more sites with primary focus as meninges (N = 3), spinal (N = 1), intestinal (N = 11), splenic (N = 3) or miliary...
(N = 4) with or without lung involvement. PTB (N = 111) had involvement of lung parenchyma exclusively. LTB (N = 47) included TB restricted to one site without lung involvement (lymph nodes = 29, peripheral joints = 9, pleural = 8 and endobronchial = 1). Patients were included in the study if they were positive by one or more of the following criteria: microscopy, culture, histology, imaging (chest X-rays for pulmonary patients and CT scan and or MRI for disseminated disease).

The control group consisted of healthy donors (TBNA = 188) with no signs, symptoms or history of previous tuberculosis. Tuberculin skin tests (TST) positivity was assessed by administering five tuberculin units intracutaneously on the volar surface of the right arm. An induration of ≥10 mm was used as a cut for positive responses (TST+) which is considered to be indicative of latent infection. The Aga Khan University Ethical Review Committee (ERC) approved the project. Written consent was obtained, for each participant or his or her guardians in case of minors after explaining the purpose of the study.

DNA Extraction
Five ml blood were collected in ACD (VWR Scientific, West Chester, PA, USA) tubes and kept frozen until use. Genomic DNA was extracted from frozen whole blood using Promega Wizard Genomic DNA Purification Kit (Promega Corporation Madison, WI, USA) according to the manufacturer’s instructions. After extraction, DNA was quantified by spectrophotometry, checked for purity and stored at −235°C until further analyses.

Molecular analysis
IFNγ and IL10 genotype analyses were carried out using amplification refractory mutation system-PCR (ARMS-PCR) [41]. Primers used for the detection of SNPs were purchased from MWG-Biotech AG, (Ebersberg, Germany). Human growth hormone and β actin were used as internal controls to check the accuracy of PCR reactions. Amplified products were monitored by electrophoresis on agarose gel containing 10 mg/ml ethidium bromide. Product bands were visualized on a transiluminator and polaroid pictures were taken for interpretation.

Table 2. Diagnostic modality used for confirmation of tuberculosis.

| Disease* category | N     | % (TST≥10 mm) | Microscopy | Culture | Histology | *Imaging | Response to treatment |
|-------------------|-------|----------------|------------|---------|-----------|----------|----------------------|
| TBNA              | 188   | 71             | -          | -       | -         | -        | -                    |
| Pulmonary         | 111   | 62             | 47         | 24      | 0         | 38       | 2                    |
| Disseminated      | 20    | 35             | 1          | 3       | 2         | 12       | 2                    |
| Localized         | 47    | 43             | 1          | 10      | 13        | 10       | 13                   |

Note: Primary diagnostic modality used diagnosis of tuberculosis.
*Criteria for disease category given in material and methods.
*Imaging tests included chest X-rays for pulmonary patients, CT scan and or MRI for disseminated disease.

doi:10.1371/journal.pone.0004778.t002

Table 3. Genotype frequencies in healthy controls and different clinical forms of tuberculosis (TB).

| Genotypes     | TBNA (188) | TBA (188) | PTB (111) | PMN (19) | PMD (63) | PAD (29) | ETB (67) | DTB (20) | LTB (47) |
|---------------|------------|-----------|-----------|----------|----------|----------|----------|----------|----------|
| IFN-γ (+874)  |            |           |           |          |          |          |          |          |          |
| TT            | 25 (13.3)  | 39 (20.74)| 27 (24.32)| 8 (42.11)| 16 (25.4)| 3 (10.34)| 12 (17.91)| 3 (15.00)| 9 (19.15)|
| TA            | 87 (46.28)| 83 (44.15)| 47 (42.34)| 6 (31.58)| 28 (44.4)| 13 (44.83)| 30 (44.78)| 8 (40.00)| 22 (46.80)|
| AA            | 76 (40.43)| 66 (35.11)| 37 (33.33)| 5 (26.32)| 19 (30.16)| 13 (44.83)| 25 (37.31)| 9 (45.00)| 16 (34.04)|
| x             | 3.86       | 6.05      | 10.69     | 5.58     | 0.30     | 0.87     | 0.29     | 1.28     |          |
| Corrected p = | 0.08       | 0.034     | 0.012     | 0.029    | 0.588    | 0.433    | 0.859    | 0.278    |          |
| Corrected p   | TBNA TST+  | 0.064     | 0.007     | 0.029    | 0.008    | 0.780    | 0.649    | 0.857    | 0.495    |

IL-10 (−1082)

| Genotypes | TBNA (188) | TBA (188) | PTB (111) | PMN (19) | PMD (63) | PAD (29) | ETB (67) | DTB (20) | LTB (47) |
|-----------|------------|-----------|-----------|----------|----------|----------|----------|----------|----------|
| GG        | 20 (10.64)| 27(14.36)| 19 (17.12)| 4 (21.05)| 7 (11.1)| 8 (27.59)| 8 (11.94)| 4 (20.00)| 4 (8.51)|
| GA        | 136 (72.34)| 132 (70.21)| 71 (63.96)| 11 (57.89)| 46 (73.02)| 14 (48.25)| 51 (76.12)| 12 (60.00)| 39 (82.98)|
| AA        | 32 (17.02)| 29 (15.43)| 21 (18.92)| 4 (21.05)| 10 (15.89)| 7 (24.14)| 8 (11.94)| 4 (20.00)| 4 (8.51)|
| x         | 1.25       | 3.09      | 2.20      | 0.05     | 8.41     | 0.98     | 1.85     | 2.52     |          |
| Corrected p = | 0.33       | 0.489     | 0.621     | 0.831    | 0.374    | 0.384    | 0.612    | 0.437    |          |
| Corrected p | TBNA TST+ | 0.435     | 0.767     | 0.945    | 0.867    | 0.341    | 0.330    | 0.582    | 0.357    |

Note: Patient stratification is given in Materials and Methods. N for each group given in brackets. Abbreviations used as in Table 1. Number (frequency) of genotypes is indicated. Pearson chi analysis was carried to determine the significance of differences.

All significant p values are indicated in bold. P approaching significance is given in italics. p<0.05 is considered significant.

doi:10.1371/journal.pone.0004778.t003
Sequencing methodology was used as a second confirmatory method on a subset of samples to verify that correct alleles were being identified by ARMS-PCR. The primers used for sequencing analyses were IFN\(\gamma\) Forward (\(5'\)-TAT GAT TGT GGC TAA GGA-3'), IFN\(\gamma\) Reverse (\(5'\)-CCC CAA TGG TAC AGG TTT CT-3') and IL-10 Forward (\(5'\)-TGT GGA AGG GGA AGG TG-3'), IL-10 Reverse (\(5'\)-TAA AAG ATG GGG TGG AAG AA-3'). These primers were designed using software Lasergene version 7.0 (DNASTar, Madison, WI, USA) and amplify a part of the gene that covers IFN\(\gamma\) (\(+874T\rightarrow A\)) or IL10 (\(-1082G\rightarrow A\)) SNPs to yield products size of 318 and 329 bp respectively. PCR products were purified with the QIAquick PCR purification kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Purified products were then sent to Macrogen for sequencing (Macrogen Inc, Seoul, Korea) with both forward and reverse primers. Sequencing results were analyzed by BLAST search of the GenBank database and EMBoss pairwise alignment of the EMBL-EBI database. There was complete concordance between PCR based and sequence based analyses for homozygous as well as heterozygous genotypes (\(+874\), \(TT=13\); \(AA=9\); \(-1082\), \(GG=6\); \(GA=17\)).

Whole blood stimulation assays

Stimulated whole blood (WB) culture assay for assessing cytokine profiles have been described in detail previously [34]. Briefly, heparinized blood was diluted 1/11 with sterile RPMI 1640 tissue culture medium containing 100 units/ml of penicillin/100 \(\mu\)g/ml streptomycin and 2 mM L-glutamine (Sigma Chemical Co., St Louis, Mo). Diluted WB (900 \(\mu\)l/well) were stimulated with MTB culture filtrate proteins [3 \(\mu\)g/ml] in a 24-well tissue culture plates (Flow Laboratories, Irvine, Scotland) within 2 hours of collection. Supernatants were collected from the wells at varying intervals and stored as 4 \times 200 \(\mu\)l aliquots at \(-35\)°C.

Cytokine assessment

Cytokine (IFN\(\gamma\) and IL10) in supernatants were assessed using pairs of monoclonal antibodies as described in detail previously [39]. Dose response curves were set up in each individual plate. Supernatants were serially diluted and optical density readings in the linear range of the dose response curve were used for calculating the concentrations. The final concentrations (pg/ml) were obtained after multiplying the values by dilutions at which the OD was read. The sensitivity and range of cytokine detection was 7.5–1000 pg/ml and was comparable to that reported by the manufacturer.

Statistical Analysis

Allelic and genotypic frequencies and multi loci analysis were compared for all groups together and for individual patient and control groups. Computer software SPSS version 16.0 and EpiInfo 2000 applications were used to carry out statistical analyses. Frequencies were compared between groups by Pearson chi-squared tests or Fisher’s exact tests, when analyzing allelic frequencies lower than five to determine statistical significance differences between groups. Odds ratios (OR) with respective confidence intervals (95% CI) for disease susceptibility were also calculated. Linear-by-linear test were used to determine the significance (corrected \(p\) values) of genotypes between TB groups and healthy controls. Multiple logistic regression analysis was applied, to determine the effect of age and sex with genotypes. Values of \(p<0.05\) were considered significant for both Pearson and linear-by-linear \(\chi^2\) test. Hardy-Weinberg proportions were determined by applying the equation \((p^2+2pq+q^2)\).

Table 4. Differences in allele frequencies in healthy controls and tuberculosis patients

|                  | N  | chi-value | corrected \(p=\) | OR  | 95% CI (lower) | 95% CI (upper) |
|------------------|----|-----------|------------------|-----|----------------|----------------|
| **IFN\(\gamma\) (+874 T\rightarrow A)** |    |           |                  |     |                |                |
| TBNA             | 188| 3.20      | 0.074            | 1.31| 0.79           | 1.75           |
| TBA              | 188| 4.78      | 0.029            | 1.46| 1.04           | 2.04           |
| PTB              | 111| 6.72      | 0.01             | 2.4 | 1.22           | 4.72           |
| PMN              | 19 | 4.95      | 0.026            | 1.59| 1.05           | 2.38           |
| PMD              | 63 | 0.29      | 0.587            | 0.85| 0.47           | 1.53           |
| PAD              | 29 | 0.46      | 0.50             | 1.15| 0.77           | 1.72           |
| ETTB             | 72 | 0.032     | 0.858            | 0.94| 0.47           | 1.86           |
| DTB              | 20 | 0.12      | 0.274            | 1.29| 0.82           | 2.05           |
| **IL-10 (−1082 G\rightarrow A)** |    |           |                  |     |                |                |
| TBNA             | 188| 0.53      | 0.48             | 1.11| 0.83           | 1.48           |
| TBA              | 188| 0.29      | 0.58             | 1.01| 0.79           | 1.54           |
| PTB              | 111| 0.14      | 0.708            | 1.14| 0.58           | 2.22           |
| PMN              | 19 | 0.025     | 0.875            | 1.03| 0.69           | 1.55           |
| PMD              | 63 | 0.49      | 0.486            | 1.22| 0.7            | 2.12           |
| PAD              | 29 | 0.036     | 0.85             | 1.04| 0.7            | 1.54           |
| ETTB             | 72 | 0.15      | 0.701            | 1.14| 0.59           | 2.18           |
| DTB              | 20 | 0.307     | 0.58             | 1.14| 0.72           | 1.79           |
| LTB              | 47 | 1.12      | 0.274            | 1.29| 0.82           | 2.05           |

Note: Patient stratification is given in material and methods. N for each group is given in brackets. Abbreviations used as in Table 1. doi:10.1371/journal.pone.0004778.t004

Statistical Analysis

Allelic and genotypic frequencies and multi loci analysis were compared for all groups together and for individual patient and control groups. Computer software SPSS version 16.0 and EpiInfo 2000 applications were used to carry out statistical analyses. Frequencies were compared between groups by Pearson chi-squared tests or Fisher’s exact tests, when analyzing allelic frequencies lower than five to determine statistical significance differences between groups. Odds ratios (OR) with respective confidence intervals (95% CI) for disease susceptibility were also calculated. Linear-by-linear test were used to determine the significance (corrected \(p\) values) of genotypes between TB groups and healthy controls. Multiple logistic regression analysis was applied, to determine the effect of age and sex with genotypes. Values of \(p<0.05\) were considered significant for both Pearson and linear-by-linear \(\chi^2\) test. Hardy-Weinberg proportions were determined by applying the equation \((p^2+2pq+q^2)\).
Acknowledgments

We are grateful to Dr. Abbas Rehmani, Consultant Chest Physician, Rima Clinic, Karachi for providing blood samples from tuberculosis patients and Dr. Bushra Moiz of The Aga Khan University for providing samples from healthy donors. Excellent support for documentation of families by Miss Farida Talat and Ms Farzana Sohan (LHV) are gratefully acknowledged. We are grateful to Dr Philippe Frossard for critical comments on the manuscript. Excellent technical support by Mr. Mohammad Anwar for blood collection, and secretarial help by Ms Regina D’souza are gratefully acknowledged.

Table 5. Genotype combination in relation to disease severity.

| IFNγ/IL10 genotypes | TBNA | PMN | PMD | PAD | DTB | LTB |
|---------------------|------|-----|-----|-----|-----|-----|
| TT/GG %             |     |     |     |     |     |     |
| chi²                |     |     |     |     |     |     |
| corrected p=        |     |     |     |     |     |     |
| OR                  |     |     |     |     |     |     |
| (95% CI)            |     |     |     |     |     |     |
| TT/AA %             |     |     |     |     |     |     |
| chi²                |     |     |     |     |     |     |
| corrected p=        |     |     |     |     |     |     |
| OR                  |     |     |     |     |     |     |
| (95% CI)            |     |     |     |     |     |     |
| TT/GA %             |     |     |     |     |     |     |
| chi²                |     |     |     |     |     |     |
| corrected p=        |     |     |     |     |     |     |
| OR                  |     |     |     |     |     |     |
| (95% CI)            |     |     |     |     |     |     |
| TA/GG %             |     |     |     |     |     |     |
| chi²                |     |     |     |     |     |     |
| corrected p=        |     |     |     |     |     |     |
| OR                  |     |     |     |     |     |     |
| (95% CI)            |     |     |     |     |     |     |
| TA/AA %             |     |     |     |     |     |     |
| chi²                |     |     |     |     |     |     |
| corrected p=        |     |     |     |     |     |     |
| OR                  |     |     |     |     |     |     |
| (95% CI)            |     |     |     |     |     |     |
| TA/GA %             |     |     |     |     |     |     |
| chi²                |     |     |     |     |     |     |
| corrected p=        |     |     |     |     |     |     |
| OR                  |     |     |     |     |     |     |
| (95% CI)            |     |     |     |     |     |     |
| AA/GG %             |     |     |     |     |     |     |
| chi²                |     |     |     |     |     |     |
| corrected p=        |     |     |     |     |     |     |
| OR                  |     |     |     |     |     |     |
| (95% CI)            |     |     |     |     |     |     |
| AA/AA %             |     |     |     |     |     |     |
| chi²                |     |     |     |     |     |     |
| corrected p=        |     |     |     |     |     |     |
| OR                  |     |     |     |     |     |     |
| (95% CI)            |     |     |     |     |     |     |

doi:10.1371/journal.pone.0004778.t005
Gene Polymorphisms in TB

Author Contributions

Performed the experiments: AA NT. Analyzed the data: AA NT. Wrote the paper: AA. Extra pulmonary patients recruitment and diagnosis: BJ. Optimization of PCR conditions and training: ZH. Design of experiment and critical reading of the manuscript: TR. Recruitment of Pulmonary patients and diagnosis: GD.

References

1. Akhtar S, Carpenter TE, Rathi SK (2007) A chain binomial model for intra-household spread of Mycobacterium tuberculosis in a low socio-economic setting in Pakistan. Epidemiol Infect 135: 27–33.
2. Dhingra VK, Rajpal S, Aggarwal N, Taneye JK (2004) Tuberculosis Trend among Household Contacts of TB Patients. Indian J Comm Med 29: 1–5.
3. Guwatudde D, Nakamoto M, Jones-Lopez EC, Magauda A, Chiumana A, et al. (2003) Tuberculosis in Household Contacts of Infectious Cases in Kampala, Uganda. Am J Epidemiol 158: 887–898.
4. Lemos AC, Matos ED, Pedral-Sampayo DB, Netto EM (2004) Risk of Tuberculosis among Household Contacts in Salvador, Bahia. Braz J Infect Dis 8: 424–430.
5. Comstock G (1982) Epidemiology of Tuberculosis. Am J Respir Dis 125: 8–15.
6. Ferraz JC, Melo FB, Albuquerque ME, Monteis C, Abath FG (2004) Immune factors and immunoregulation in tuberculosis. Braz J Med Biol Res 39: 1397–1397.
7. Dorman SE, Picard C, Lammas D, Hayne K, Van de Jelst, et al. (2004) Clinical findings of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet 364: 2113–2121.
8. Alhore F, Josangue F, Lanhamed-Chehadi R, Fane,Fonc pheniec MC, Fizame C, et al. (1998) A causative relationship between mutant IFNγR1 alleles and impaired cellular response to IFN gamma in a compound heterozygous child. Am J Hum Genet 62: 723–726.
9. Pacheco AG, Cardoso CC, Moraes MO (2008) IFNG -1082 G/A and TNF -308 G/A polymorphisms in association with tuberculosis susceptibility: a meta-analysis study. Hum Genet 123: 477–484.
10. Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV (2000) A single nucleotide polymorphism in the first intron of human interferon gamma gene: absolute correlation with a polymorphic C/A microsatellite marker of high interferon gamma production. Human Immunology 61: 863–866.
11. Rees LE, Wood NA, Gillespie KM, Lai KN, Gusto K, et al. (2002) The interleukin 10-1002 A/G polymorphism: allele frequency in different populations and functional significance. Cell Mol Life Sci 59: 560–569.
12. Ates O, Musellin B, Ongen G, Topal-Sarikaya A (2007) Interleukin-10 and Tumor Necrosis Factor-alpha Gene Polymorphism in Tuberculosis. J Clin Immunol pp 1–5.
13. Oh JH, Yang CS, Noh VK, Kween YM, Jung S-S, et al. (2007) Polymorphism of interferon-10 and tumour necrosis factor-gene alleles are associated with newly diagnosed and recurrent pulmonary tuberculosis. Respiratory 12: 394–398.
14. Flynn JL, Chan J, Triefzklj BH, Dalton D, Stewart TA, et al. (1993) An Essential role for Interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 170: 2297–2297.
15. O’Garra A, Vieira S, Guerra P, Vieira PL, Goldfeld AE (2004) IL-10 producing and gamma interferon response. J Immunol 174: 255–259.
16. Jamil B, Shahid F, Hasan Z, Nasir N, Razzaki T, et al. (2007) Interferongamma +1082 G/A polymorphism: allele frequency in different populations and functional significance. Cell Mol Life Sci 59: 560–569.
17. Pacheco AG, Cardoso CC, Moraes MO (2008) IFNG -1082 G/A and TNF -308 G/A polymorphisms in association with tuberculosis susceptibility: a meta-analysis study. Hum Genet 123: 477–484.
18. Pacheco AG, Cardoso CC, Moraes MO (2008) IFNG -1082 G/A and TNF -308 G/A polymorphisms in association with tuberculosis susceptibility: a meta-analysis study. Hum Genet 123: 477–484.
19. Pacheco AG, Cardoso CC, Moraes MO (2008) IFNG -1082 G/A and TNF -308 G/A polymorphisms in association with tuberculosis susceptibility: a meta-analysis study. Hum Genet 123: 477–484.
20. Takiff HE (2007) Host Genetics and Susceptibility. In: Palomino JC, Leao SC, Ritacco V, eds (2007) Tuberculosis 2007 - From Basic Science to Patient Care. Kluwer Academic/Plenum Publishers. pp 35–47.
21. Lio D, Marino V, Serauto A, Gioia V, Scola L, et al. (2002) Genotype frequencies of the +874 T-A polymorphism in the IFN-g gene and susceptibility to TB. Int J Tuberc Lung Dis 11: 113–115.
22. Shin HD, Park BL, Kim LH, Cheong HS, Lee IH, et al. (2005) Common polymorphisms in interferon-gamma, interleukin-10, transforming growth factor-b and tumor necrosis factor-alpha genes: a technical report. Transpl Immunol 6: 193–197.

Acknowledged. We are grateful to Ms Maqboola Dojki and Ms Firdaus with help in statistical analysis. We acknowledge KIBGE, University of Karachi, for providing research and office space during Dr. Rabia Hussain’s sabbatical during February–April 2005.